%PDF-1.4
%
1 0 obj
<>]>>/Pages 2 0 R/Type/Catalog>>
endobj
48 0 obj
<>stream
Creo Normalizer JTP
2024-03-19T06:00:50-07:00
2007-05-23T11:56:09-04:00
2024-03-19T06:00:50-07:00
uuid:f67a9d3e-a5be-4adf-bb6a-8f2f99f3ce9c
uuid:fb883932-1dd1-11b2-0a00-d300a8d6faff
application/pdf
endstream
endobj
2 0 obj
<>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[9.0 9.0 594.0 792.0]/Type/Page>>
endobj
49 0 obj
[55 0 R]
endobj
45 0 obj
<>
endobj
50 0 obj
<>stream
BT
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
10 0 0 10 92.1648 600.3835 Tm
[(Review)-332.9 (Articles)]TJ
/T1_1 1 Tf
0 -1.2 TD
[(Neurotoxicity)-332.9 (and)-332.9 (Metabolism)-332.9 (of)-332.9 (the)-332.9 (Catecholamine-Derived)-332.9 (3,4-)]TJ
1 -1 Td
[(Dihydroxyphenylacetaldehyde)-332.9 (and)-332.9 (3,4-Dihydroxyphenylglycolaldehyde:)]TJ
0 -1 TD
[(The)-332.9 (Role)-332.9 (of)-332.9 (Aldehyde)-332.9 (Dehydrogenase)]TJ
/T1_2 1 Tf
1 -1 Td
[(Satori)-332.9 (A.)-333 (Marchitti,)-333 (Richard)-332.9 (A.)-333 (Deitrich,)-333 (and)-332.9 (Vasilis)-332.9 (Vasiliou)]TJ
/T1_1 1 Tf
39.7 3 Td
(125)Tj
-41.7 -5.2 Td
[(Pharmacological)-332.9 (Treatment)-332.9 (of)-333 (the)-332.9 (Overweight)-333 (Patient)]TJ
/T1_2 1 Tf
2 -1 Td
[(George)-332.9 (A.)-332.9 (Bray)-332.9 (and)-332.9 (Frank)-332.9 (L.)-332.9 (Greenway)]TJ
/T1_1 1 Tf
39.7 1 Td
(151)Tj
-41.7 -3.2 Td
[(Nonclassic)-332.9 (Endogenous)-332.9 (Regulators)-332.9 (of)-333 (Angiogenesis)]TJ
/T1_2 1 Tf
2 -1 Td
[(Domenico)-332.9 (Ribatti,)-333 (Maria)-332.9 (Teresa)-332.9 (Conconi,)-333 (and)-332.9 (Gastone)-332.9 (G.)-333 (Nussdorfer)]TJ
/T1_1 1 Tf
39.7 1 Td
(185)Tj
/T1_0 1 Tf
-41.7 -3.2 Td
(Erratum)Tj
/T1_1 1 Tf
0 -1.2 TD
[(Correction)-332.9 (to)-332.9 (\223Emerging)-332.9 (Roles)-333 (for)-332.9 (Ubiquitin)-332.9 (and)-332.9 (Protein)-333 (Degradation)-332.9 (in)-332.9 (Neuronal)]TJ
1 -1 Td
(Function\224)Tj
40.7 1 Td
(206)Tj
/T1_2 1 Tf
-40.2 -39.3 Td
[(About)-547.4 (the)-547.4 (cover:)]TJ
/T1_1 1 Tf
7.7598 0 Td
[(Formation)-547.4 (and)-547.4 (metabolism)-547.4 (of)-547.4 (DOPAL)-547.4 (and)-547.4 (DOPEGAL.)-547.4 (See)-547.4 (the)-547.4 (article)-547.4 (by)]TJ
-7.7598 -1.2 Td
[(Marchitti)-332.9 (et)-333 (al.)-333 (on)-332.9 (page)-332.9 (125)-332.9 (of)-333 (this)-332.9 (issue.)]TJ
ET
/CS0 CS 1 SCN
52 w
/GS1 gs
92.165 63.384 m
95.165 63.384 l
S
3 w
95.165 87.884 m
524.165 87.884 l
S
52 w
521.165 63.384 m
524.165 63.384 l
S
3 w
92.165 38.884 m
521.165 38.884 l
S
BT
/T1_3 1 Tf
32 0 0 32 123.7471 734.3835 Tm
(PHARMACOLOGICAL)Tj
4.1246 -1.3125 Td
(REVIEWS)Tj
/T1_4 1 Tf
9 0 0 9 129.3097 676.3835 Tm
[(A)-332.7 (Publication)-332.7 (of)-332.7 (the)-332.7 (American)-332.7 (Society)-332.7 (for)-332.7 (Pharmacology)-332.7 (and)-332.7 (Experimental)-332.7 (Therapeutics)]TJ
ET
1 w
50.165 666.384 m
566.165 666.384 l
S
BT
/T1_4 1 Tf
12 0 0 12 50.1648 650.8835 Tm
[(June)-332.9 (2007)]TJ
33.2758 0 Td
[(Volume)-277.9 (59,)-277.9 (Number)-277.9 (2)]TJ
ET
BT
0 g
/GS2 gs
/T1_5 1 Tf
0 -11 11 0 584 188.18092 Tm
(at ASPET Journals on March 19, 2024)Tj
/GS2 gs
-11.19199 0 Td
(pharmrev.aspetjournals.org )Tj
/GS2 gs
-7.55398 0 Td
(Downloaded from )Tj
ET
endstream
endobj
30 0 obj
<>
endobj
9 0 obj
<>
endobj
12 0 obj
<>
endobj
15 0 obj
<>
endobj
18 0 obj
<>
endobj
21 0 obj
<>
endobj
54 0 obj
<>
endobj
22 0 obj
<>
endobj
23 0 obj
<>stream
H|T PW:mJk)"QQXYQv@XA%SKM5z#xVhhתO*&nvvS^~aX&LKaj-+-N*X{hp4.zj*72>,[gbA*{%CQqq܂9mUQmyyꊅ{v-7lN\<{#S=7?'XP7y7_Tb d"_ e!#r(@1`Ff$H!z/y93hlȧ*TX4':Zײ7h8Vi(Ϗ*Yڏ:2tC0q%^>`/HBy;/| _r=zqo
?W`wDnhTTҶV\a;g?hm{/rځwalX1懔R*4SbPz||N
ǂ*NJJc#&M*P`g#r\a籇q h>
Nw(1dsKd=p86ئmU4'4c107{/Pj0)I/>=ڰaA2COښ s@#4!N$nӵQ]o`(2B$/% (~{_8m&ŀhHu>V&UK}JllURxz(e\!5 &6MW7p
ED]Oe}Xl*B f DLke3NpԎ J&Z<d2-q܇jc$0{Y-*w٤B:J}t݁R&6@}="m+scڷKHE?&v-*G3(6xy5\k 7?m<-<{歏${?r疩M%3N&\>ӦTa~[o[T$$\X7oR\]
wz{B݅
cxøe WoMB#=*6¤H^UYK~CDz57~,ٵب
G28+''NOoGK_OCjT`}zO/7'/a3p f;|sB-I$(k<ȿ_,&Tors\|C`|^?MyQl:*˝0iU
?fu`ӋtSJrJ'/3o.s倹6;J8PvgwД7}b=,lcfVUo=Y3}ʧ;Or?*w?֠bX56?2Ys+2&Meo7su>l竚3nlߗNz??,
` J
endstream
endobj
19 0 obj
<>
endobj
20 0 obj
<>stream
Hip%cYe쫪!CJp&fpZ[Oٖeɖv]iwecB\;1Ch;:@@JM2]m
C?;;UI*ZfկX#<'RR0z:Trbz귞k3i`ThMjP%յK텕YtR<~CmET_kηZs+/__o0[{E\}eynє[^UJתR**լ$jZ@ZVMU UII{'4)Ri!'gN9FnZCsaD'7BIHfZP}s NDvYx)/LdVB:oN >GP|zw+Z O"AN
ҜSJ\xT'4A|א,} <γ/n~
h'N,}?nَ>Lts[N1 ;(&1"fu4um5HNkzEp^Y+dKz-),zJX+4/$V`.?%0{U{KN~@.#Ԛxz8|vp ̀qok6(Oe\kTU{dK{H|LJ)8?w@%]~M
$m` 紖9gYY|~6Vo]~ۈx8G$v1%)Mz7It0_S`P+r@:ծOf'N\GxcXx<na_3%ߌIh2>F"zI+BbEV1x%U+&[`FIz$
tC~v/wvY \P"9ر.1e$PO2n*ȄA/c7nhm^$*
p,S\>NJfN^eJ*- ̀&2'KTAk A{gyBL& P[A;@k'ቱ<'&Vh@fpO') '$W
Mc'
Wh5O$'֞S
Q {`
P3qVYHd<OO6wSrU izh&QGGM466XgJ͔},u?K%t7UJ?Qã̭$]n6c.YјvOXSÛ#M[8xẏQ!_D~s3Rx-E}I1f05NӁ6/6`/ç>O>}]`Ng<.IwoH54@rz6PlGkac\80h)}?>#gQ
y!!t@sg>XhL#iz
ACě$Y
):;/wh*]rg/4]JpneAtنFGxæ"\ZX+υ3eN>!k2y"r1C:yKaA6Jy@~h%H+mx<8ߊt=>sA#P3یwq ofJnR >'D
34 4PU\ƀNY7+D
Sڅ1/Gq(;q|t!&*8^
cA<w&m>J 1mH}Wg9iTb`
_?̇߾}*v1EmZKE֯CWt7qOya9To>^nE+ y&#ż3nwSMن%OphHؽ7/ʩw KfʾؙCW pTʄ)Qvͺawq+_e0wÃ+a"pxw%K\ZV_N1MPu|{OTuxvTط\}ť&˚~m\z~aY"x|~sI`@Z}Y[rhRV"|T vynqdf*ҹĖj`aV"|}{}vth ;yHd~oVy.z}Q_TW"}sfzG
E b
endstream
endobj
16 0 obj
<>
endobj
17 0 obj
<>stream
HTTkTSW!ܛX!(QћکvhY"($b BB$*J +h:]QGqƮ}ɬ
?:}9p^qK܆ |""F'KݿÈ8l~̜YcFCE<=gfM04\_X˲E%W}bϮ|v{4dZ+$1ByR)DI}xB*/ao Id
ID)O͐s%ͲBH* I-xP.{Y\&UD1,Dr?w~J[6c[ql'Rlf/7opChډֽ7}tu@D@m ~{@PzkCB#c_R#T}*{^Fe&diD\ar б|
ZPceL7kzӈDC0:UEc."ѳDHϊk+-E(mE;zQΉ]s?ld
u
ﲾP@iк%,E0;`/sf
*4ȼppq.z5l}zE7eAeQx
(P`:"n>ALYۀ%T~q5zH`8W;J*]. &N/לaݶxjJN3qHovlS-T!I`8Z͗CYQ%#X <>$Ilg7EҘjg
g&]f*S
iajYB"{w1!v-tJFp>a`a:ڧzMN26f| !0S 5eѨncUQ՛+>AmZ dm$je
]k7+f~U7Xbz;]G.yfd* uEUR7j=E%m:B1y?{(o#{U?nj54*3NzeH>`m